NL-OMON46421已完成不适用
Assessment of safety, tolerability, pharmacokinetics and pharmacodynamics of multiple oral doses of the combination of GLPG2451 and GLPG2222, with or without GLPG2737, in adult subjects with cystic fibrosis - Falcon
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Galapagos NV
- 入组人数
- 6
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •* Female or male subject *18 years of age, on the day of signing the ICF;* Confirmed clinical diagnosis of CF (documented in the subject*s medical record). ;* Eligible CFTR genotype at screening:;- Cohort A: Homozygous for the F508del CFTR mutation;- Cohort B: Heterozygous for the F508del CFTR mutation with a potentiator non-responsive mutation on the second allele;- Cohort C: Homozygous for the F508del CFTR mutation;* A body weight of *40 kg at screening. ;* Stable concomitant medication for pulmonary health for CF for at least 4 weeks prior to the first study drug administration and planned continuation of the same concomitant medication for the duration of the dosing period of the study. Subjects with diabetes mellitus and/or pancreatic insufficiency are eligible for the study provided they are on stable treatment (e.g. medication, diet, pancreatic enzyme replacement therapy) for at least 4 weeks prior to the first study drug administration in the opinion of the investigator.;* Forced expiratory volume in 1 second (FEV1): 40% * FEV1 * 90% of predicted normal for age, sex, and height at screening (pre- or post-bronchodilator) at screening. ;* Sweat chloride concentration *60 mmol/L at screening.;* Non-smoker and non-user of any nicotine and or cannabis containing products. A non-smoker is defined as an individual who has abstained from smoking for at least 1 year prior to the screening. A non-user is defined as an individual who has abstained from any nicotine containing products for at least 1 year prior to the screening.;Reference is made to the protocol for a complete overview of the inclusion criteria.
排除标准
- •* History of or ongoing allergic bronchopulmonary aspergillosis.;* Medical history of cataract (or lens opacity) and/or glaucoma.;* Cataract (or lens opacity) and/or glaucoma determined by an ophthalmologist during the screening period.;* Unstable pulmonary status or respiratory tract infection (including rhinosinusitis) requiring a change in therapy within 4 weeks prior to the first study drug administration.;* History of clinically meaningful unstable or uncontrolled chronic disease that makes the subject unsuitable for inclusion in the study in the opinion of the investigator.;* Need for supplemental oxygen during the day, and >2 L/minute while sleeping.;* History of hepatic cirrhosis with portal hypertension (e.g., signs/symptoms of splenomegaly, esophageal varices).;* History of malignancy within the past 5 years (except for basal cell carcinoma of the skin with no evidence of recurrence and/or carcinoma in situ of the cervix that has been treated with no evidence of recurrence).;* Use of any moderate and strong inhibitor(s) or inducer(s) of CYP3A4 within 4 weeks prior to the first study drug administration (e.g., clarithromycin, itraconazole, ketoconazole, telithromycin, rifampin, carbamazepine).;* Use of CFTR modulator therapy (e.g., lumacaftor and/or ivacaftor) within 4 weeks prior to the first study drug administration.;* Use of any oral corticosteroid within 3 months of screening; or history of oral corticosteroid use for *30 days (cumulative) within 2 years of screening.;* Abnormal liver function test at screening; defined as AST and/or ALT and/or alkaline phosphatase and/or gamma-glutamyl transferase (GGT) *3× the upper limit of normal (ULN); and/or total bilirubin *1.5× the ULN.;Reference is made to the protocol for a complete overview of the exclusion criteria.
研究者
相似试验
已完成
不适用
Assessment of safety, tolerability and pharmacokinetics of single and multiple ascending oral doses of GLPG2451 and of the combination of GLPG2451 and GLPG2222 in healthy female subjects.cystic fibrosisTaaislijmziekte, cystische fibroseNL-OMON42997Galapagos SAS56
已完成
不适用
Evaluation of the safety, tolerability, pharmacokinetics and pharmacodynamics of topically applied NT-077 (tiotropium bromide) in healthy volunteers.hyperhydrosisprimary hyperhidrosis is a not well-delineated conditionexcessive sweat productionNL-OMON50872otoxins Holding B.V.4
已完成
不适用
Pharmacokinetics and safety of DA-6034KCT0000793Dong-A Pharm67
已完成
不适用
EVALUATION OF SAFETY, TOLERABILITY AND PHARMACOKINETIC CHARACTERISTICS OF MULTIPLE-ASCENDING DOSES OF CG400549 IN HEALTHY VOLUNTEERSMRSA10004018NL-OMON34490Crystal Genomics24
已完成
不适用
Evaluating the safety, tolerability, and pharmacodynamic properties of IW-6463 in healthy elderly subjects.Alzheimer's diseaseDementiaNL-OMON48314Cyclerion Therapeutics, Inc.24